Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

chronicDiaSorin SpA Launches The HCG Test For Early Detection Of Pregnancy On Its Liaison XL In US Market Following Approval By FDA


Tuesday, 24 Sep 2013 06:36am EDT 

DiaSorin SpA announced that it received the clearance for the LIAISON XL hCG test from the Food and Drug Administration (FDA) for the US market. The hCG test is an In Vitro Immunoassay for the quantitative determination of total human chronic gonadotropin (hCG and hCG) in human serum for early detection of pregnancy, which can be performed on the LIAISON XL Analyzer. The launch of the new LIAISON XL hCG assay to the LIAISON menu, in addition to the other DiaSorin's Fertility tests already approved by the FDA (LH, FSH, Prolactin, Progesterone, Estradiol, and Testosterone) completes the DiaSorin Fertility panel, and strengthens the menu offer in the US market. 

Company Quote

33.23
-0.36 -1.07%
23 Dec 2014